Payment overview · 2025
General Payments
$213.28
9 reported records · 6 companies
Healthcare provider profile · identity verified
Judith Valencia, MD
Allopathic & Osteopathic Physicians|Pediatrics · MIAMI, FL · NPI 1649478389
Verified facts
What the public records show
CMS Open Payments records show Judith Valencia, MD received $213.28 in general payments during 2025 across 9 reported records.
AstraZeneca Pharmaceuticals LP accounted for 42.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $90.82 | 42.6% | 4 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $38.55 | 18.1% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $25.65 | 12.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.67 | 9.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.45 | 9.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.14 | 8.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $213.28 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $90.82 | 4 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $38.55 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $25.65 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $25.65 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
46 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
74 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 458 | 138 |
| Atorvastatin Calcium | Atorvastatin Calcium | 413 | 147 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 299 | 97 |
| Famotidine | Famotidine | 294 | 120 |
| Lisinopril | Lisinopril | 270 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 236 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 195 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 189 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 184 | 65 |
| Metformin Hcl | Metformin Hcl | 184 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 174 | 49 |
| Alprazolam | Alprazolam | 170 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 166 | 59 |
| Gabapentin | Gabapentin | 166 | 64 |
| Omeprazole | Omeprazole | 149 | 65 |
| Azithromycin | Azithromycin | 145 | 110 |
| Ibuprofen | Ibuprofen | 131 | 61 |
| Montelukast Sodium | Montelukast Sodium | 105 | 30 |
| Fenofibrate | Fenofibrate | 101 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 99 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 98 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 44 |
| Temazepam | Temazepam | 94 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 92 | 76 |
| Ezetimibe | Ezetimibe | 90 | 29 |
| Clonazepam | Clonazepam | 89 | 13 |
| Alendronate Sodium | Alendronate Sodium | 88 | 30 |
| Methylprednisolone | Methylprednisolone | 85 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 32 |
| Simvastatin | Simvastatin | 83 | 23 |
| Sertraline Hcl | Sertraline Hcl | 82 | 28 |
| Ozempic | Semaglutide | 78 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 29 |
| Eliquis | Apixaban | 74 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 71 | 41 |
| Glimepiride | Glimepiride | 69 | 24 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 65 | suppressed |
| Carvedilol | Carvedilol | 62 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 18 |
| Donepezil Hcl | Donepezil Hcl | 59 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 58 | 41 |
| Atenolol | Atenolol | 56 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 40 |
| Meclizine Hcl | Meclizine Hcl | 52 | 26 |
| Mupirocin | Mupirocin | 52 | 33 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 37 |
| Trazodone Hcl | Trazodone Hcl | 50 | 16 |
| Furosemide | Furosemide | 49 | 20 |
| Ketoconazole | Ketoconazole | 47 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 46 | 23 |
| Synthroid | Levothyroxine Sodium | 46 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 26 |
| Folic Acid | Folic Acid | 45 | 14 |
| Lorazepam | Lorazepam | 45 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 26 |
| Meloxicam | Meloxicam | 44 | 22 |
| Nifedipine Er | Nifedipine | 44 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | 13 |
| Ssd | Silver Sulfadiazine | 44 | 24 |
| Memantine Hcl | Memantine Hcl | 42 | 18 |
| Prednisone | Prednisone | 42 | 33 |
| Baclofen | Baclofen | 40 | 19 |
| Januvia | Sitagliptin Phosphate | 40 | 13 |
| Benzonatate | Benzonatate | 37 | 22 |
| Breyna | Budesonide/Formoterol Fumarate | 37 | 15 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 37 | 29 |
| Tadalafil | Tadalafil | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Levofloxacin | Levofloxacin | 36 | 33 |
| Cephalexin | Cephalexin | 35 | 30 |
| Metronidazole | Metronidazole | 35 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 31 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | 13 |
| Carbamazepine Er | Carbamazepine | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Ciclopirox | Ciclopirox | 25 | 17 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Nystatin | Nystatin | 23 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | 12 |
| Ammonium Lactate | Ammonium Lactate | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 14 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Mupirocin | Mupirocin Calcium | 14 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 14 | 11 |
| Prolia | Denosumab | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Soaanz | Torsemide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $213.28 · 9 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, ELIQUIS, NURTEC ODT, Natroba, REPATHA, Spinosad | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error